KANDELA-302NCT07492641
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 206 → 241 locations
- Minor Trial sites expanded: 189 → 206 locations
- Minor Trial sites expanded: 162 → 189 locations
- Notable Eligibility criteria expanded, about 7 words
- Trial sites expanded: 108 → 162 locations
- Secondary endpoints: details revised at 1 of 9 entries
- Minor Trial sites expanded: 90 → 108 locationsv10
- Minor Trial sites expanded: 74 → 90 locationsv9
- Minor Trial sites expanded: 62 → 74 locationsv8
- Minor Trial sites expanded: 30 → 62 locationsv7
- Minor Trial sites expanded: 13 → 30 locationsv6
- Minor Start date: May 20, 2026 to May 22, 2026v5
- Minor Trial sites expanded: 4 → 13 locationsv4
- Notable Recruitment opened
- Trial sites expanded: 0 → 4 locations
- Start date changed from estimate of May 11, 2026 to May 20, 2026
- Notable Eligibility criteria expanded, about 27 words
- Secondary endpoints: 8 to 9
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression-Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Timeframe: Up to approximately 4 years
Secondary (9)
Overall Survival (OS)
Overall Response Rate (ORR)
Duration of Response (DOR)
PFS Determined by Investigator
Clinical Benefit Rate (CBR)
Show 4 moreShow less
Time to Response (TTR)
Number of Participants with Adverse Events (AEs)
Change from Baseline in European Organisation for Research and Treatment of Cancer (EORTC)-Item Library (IL)454.
Progression-Free Survival 2 (PFS2)
Arms and interventions
Arm A: BGB-43395 + LetrozoleExperimental
Participants will receive BGB-43395 in combination with letrozole.
Arm B: Cyclin-Dependent Kinase 4/6 Inhibitor + LetrozoleActive comparator
Participants will receive either abemaciclib, palbociclib, or ribociclib based on the Investigator's choice in combination with letrozole.
Drugs: BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib
Sites
241 sites in 16 countries
United States 84, China 33, South Korea 25, Japan 19, Brazil 13, Spain 12, Malaysia 9, Australia 8, Poland 8, Turkey (Türkiye) 8, France 7, Germany 4, Italy 4, Taiwan 4, United Kingdom 2, Puerto Rico 1